Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Блокатор рецепторов ангиотензина II олмесартан в прерывании сердечно-сосудистого и кардиоренального континуума: антигипертензивные и нефропротективные эффекты (часть 1)
Блокатор рецепторов ангиотензина II олмесартан в прерывании сердечно-сосудистого и кардиоренального континуума: антигипертензивные и нефропротективные эффекты (часть 1)
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлен обзор эффективности и переносимости одного из представителей класса блокаторов рецепторов ангиотензина II – олмесартана медоксомила (Кардосал®). Проанализированы фармакологические особенности и ангигипертензивная активность олмесартана медоксомила при монотерапии, в комбинации с другими антигипертензивными препаратами, у разных групп пациентов. В статье изложены нефропротективные свойства препарата, профиль его безопасности. Также рассматриваются причины низкой приверженности терапии пациентов, страдающих артериальной гипертонией.
Ключевые слова: артериальная гипертония, олмесартан медоксомил, нефропротекция.
Key words: arterial hypertension, olmesartan medoxomil, nephroprotection.
Ключевые слова: артериальная гипертония, олмесартан медоксомил, нефропротекция.
________________________________________________
Key words: arterial hypertension, olmesartan medoxomil, nephroprotection.
Полный текст
Список литературы
1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the on management of arterial hypertension. Eur Heart J 2013. Doi:10.1093/eurheartj/eht151.
2. James PA, Oparil S, Carter BL et al. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014. Doi: 10.1001/jama.2013.284427.
3. Mancini GBJ, Etminan M, Zhang B et al. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. JACC 2006; 47 (12): 2554–60.
4. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98 (1): 121–8.
5. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003; 163 (10): 1155–64.
6. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005; 23 (Suppl. 1): S9–17.
7. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21 (1): 20–7.
8. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90 (4): 449–55.
9. Papademetriou V. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events. Am Heart J 2009; 157 (6 Suppl. 1): S25–30.
10. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
11. Carey RM, Wang ZQ, Sigary HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155–63.
12. Scott LJ, McCormack PL. Olmesartan: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239–72.
13. Mire DE, Silfani TN, Pugsley MK. A Review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46: 585–93.
14. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS0866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181–8.
15. Warne GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345–53.
16. Agata J, Ura N, Yoshida H et al. Олмесартан – блокатор рецепторов к ангиотензину II, обладающий ингибиторным эффектом на ангиотензинпревращающий фермент. Hypertens Res 2006; 29 (11): 865–74.
17. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001; 19 (S1): S15–S20.
18. Giles TD, Robinson TD. Effects of Olmesartan Medoxomil on Systolic Blood Pressure and Pulse Pressure in the Management of Hypertension. Am J Hypertens 2004;17: 690–5.
19. Ichikawa S, Takayama Y. Long-term effects of Olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001; 24 (4): 641–6.
20. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of Olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3 (5): 283–92.
21. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23 (7): 419–30.
22. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239–72.
23. Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging 2009; 26: 61–76.
24. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007; 25: 2168–77.
25. Малакко Э., Омбони С., Вульпе М. и др. Антигипертензивная эффективность и безопасность олмесартана медоксомила и рамиприла у пожилых пациентов с мягкой и умеренной эссенциальной гипертензией: результаты исследования ESPORT. Рос. кардиол. журн. 2012; 1 (93): 8–18.
26. Nakayama S, Watada H, Mita T et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31 (1): 7–13.
27. Menne J, Jr Izzo JL, Ito S et al. For the ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012; 30: 811–8.
28. Yanagi M, Tamura K, Fujikawa T et al. The ahgionetsin II type 1 receptor bloker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res 2012; 15. Doi:10.1038/hr.2012.184.
29. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313–21.
30. Chrysant SG et al. Evaluation of antihypertensive therapy with the combination of Olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252–9.
31. Rump LC, Ambrosioni E. Initial combination therapy with Olmesartan/hydrochlorothiazide shows superior blood pressure control rate in moderate to severe. Hypertension ESC/ESH 14th Annual Meeting, Paris, 2004.
32. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens 2004; 6 (10): 569–77.
33. Palatini P. Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined With Diuretics. J Clin Hypertens 2005; 7 (2): 96–101.
34. Chrysant SG, Melino M, Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
35. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8.
36. Koc Y, Mazi E, Sakaci T. Effect of olmesartan on cystain C level in the patients with essential hypertension. Eur Rev Med Pharmacol Sci 2011; 55 (12): 1388–94.
37. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blokade reduces (itra) renal vascular resistence in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16 (4): 1135–40.
38. Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117–8.
39. Rodrìguez-Iturbe B, Sato T, Quiroz Y. AT1-receptor blockade prevents proteinuria, renal failure, hyperlipidemia and glomerulosclerosis in the Imai rat. Kidney Int 2004; 66: 668–75.
40. Yoshida K, Xu HL, Kawamura T et al. Chronic Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism in Rats With Chronic Renal Failure. J Cardiovasc Pharmacol 2002; 40: 533–42.
41. Koga K, Yamagishi S, Takeuchi M et al. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med 2002; 8 (10): 591–9.
42. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event Incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (S.1): S41–S48.
43. Бубнова М.Г., Оганов Р.Г. Лечение пациентов с артериальной гипертонией и дополнительными факторами риска в клинической практике. Программа наблюдения «ПРОГНОЗ». Терапевт. арх. 2009; 81 (9): 1–4.
44. Rumsfeld JS, Masoudi FA. Effect of Medication Nonadherence on Hospitalization and Mortality Among Patients With Diabetes Mellitus. Arch Intern Med 2006; 166: 1836–41.
45. Breekveldt-Postma NS, Siiskonen SJ, Penning-van Beest FJA et al. Non-persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. Value Health 2006; 9: A339.
46. Perreault S, Dragomir A, Roy L et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010; 69: 74–84.
47. Perreault S, Dragomir A, Roy L et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266: 207–18.
48. Kettani FZ, Dragomir A, Cote R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213–20.
2. James PA, Oparil S, Carter BL et al. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014. Doi: 10.1001/jama.2013.284427.
3. Mancini GBJ, Etminan M, Zhang B et al. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. JACC 2006; 47 (12): 2554–60.
4. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98 (1): 121–8.
5. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003; 163 (10): 1155–64.
6. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005; 23 (Suppl. 1): S9–17.
7. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21 (1): 20–7.
8. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90 (4): 449–55.
9. Papademetriou V. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events. Am Heart J 2009; 157 (6 Suppl. 1): S25–30.
10. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
11. Carey RM, Wang ZQ, Sigary HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155–63.
12. Scott LJ, McCormack PL. Olmesartan: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239–72.
13. Mire DE, Silfani TN, Pugsley MK. A Review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46: 585–93.
14. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS0866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181–8.
15. Warne GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345–53.
16. Agata J, Ura N, Yoshida H et al. Олмесартан – блокатор рецепторов к ангиотензину II, обладающий ингибиторным эффектом на ангиотензинпревращающий фермент. Hypertens Res 2006; 29 (11): 865–74.
17. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001; 19 (S1): S15–S20.
18. Giles TD, Robinson TD. Effects of Olmesartan Medoxomil on Systolic Blood Pressure and Pulse Pressure in the Management of Hypertension. Am J Hypertens 2004;17: 690–5.
19. Ichikawa S, Takayama Y. Long-term effects of Olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001; 24 (4): 641–6.
20. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of Olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3 (5): 283–92.
21. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23 (7): 419–30.
22. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239–72.
23. Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging 2009; 26: 61–76.
24. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007; 25: 2168–77.
25. Малакко Э., Омбони С., Вульпе М. и др. Антигипертензивная эффективность и безопасность олмесартана медоксомила и рамиприла у пожилых пациентов с мягкой и умеренной эссенциальной гипертензией: результаты исследования ESPORT. Рос. кардиол. журн. 2012; 1 (93): 8–18.
26. Nakayama S, Watada H, Mita T et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31 (1): 7–13.
27. Menne J, Jr Izzo JL, Ito S et al. For the ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012; 30: 811–8.
28. Yanagi M, Tamura K, Fujikawa T et al. The ahgionetsin II type 1 receptor bloker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res 2012; 15. Doi:10.1038/hr.2012.184.
29. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313–21.
30. Chrysant SG et al. Evaluation of antihypertensive therapy with the combination of Olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252–9.
31. Rump LC, Ambrosioni E. Initial combination therapy with Olmesartan/hydrochlorothiazide shows superior blood pressure control rate in moderate to severe. Hypertension ESC/ESH 14th Annual Meeting, Paris, 2004.
32. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens 2004; 6 (10): 569–77.
33. Palatini P. Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined With Diuretics. J Clin Hypertens 2005; 7 (2): 96–101.
34. Chrysant SG, Melino M, Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
35. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8.
36. Koc Y, Mazi E, Sakaci T. Effect of olmesartan on cystain C level in the patients with essential hypertension. Eur Rev Med Pharmacol Sci 2011; 55 (12): 1388–94.
37. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blokade reduces (itra) renal vascular resistence in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16 (4): 1135–40.
38. Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117–8.
39. Rodrìguez-Iturbe B, Sato T, Quiroz Y. AT1-receptor blockade prevents proteinuria, renal failure, hyperlipidemia and glomerulosclerosis in the Imai rat. Kidney Int 2004; 66: 668–75.
40. Yoshida K, Xu HL, Kawamura T et al. Chronic Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism in Rats With Chronic Renal Failure. J Cardiovasc Pharmacol 2002; 40: 533–42.
41. Koga K, Yamagishi S, Takeuchi M et al. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med 2002; 8 (10): 591–9.
42. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event Incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (S.1): S41–S48.
43. Бубнова М.Г., Оганов Р.Г. Лечение пациентов с артериальной гипертонией и дополнительными факторами риска в клинической практике. Программа наблюдения «ПРОГНОЗ». Терапевт. арх. 2009; 81 (9): 1–4.
44. Rumsfeld JS, Masoudi FA. Effect of Medication Nonadherence on Hospitalization and Mortality Among Patients With Diabetes Mellitus. Arch Intern Med 2006; 166: 1836–41.
45. Breekveldt-Postma NS, Siiskonen SJ, Penning-van Beest FJA et al. Non-persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. Value Health 2006; 9: A339.
46. Perreault S, Dragomir A, Roy L et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010; 69: 74–84.
47. Perreault S, Dragomir A, Roy L et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266: 207–18.
48. Kettani FZ, Dragomir A, Cote R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213–20.
Авторы
М.Г.Бубнова
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва
mbubnova@gnicpm.ru
State Research Center of Preventive Medicine Russia, Moscow
mbubnova@gnicpm.ru
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва
mbubnova@gnicpm.ru
________________________________________________
State Research Center of Preventive Medicine Russia, Moscow
mbubnova@gnicpm.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.